• Publications
  • Influence
Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues
The authors' results confirmed previously reported data in the literature concerning isoforms expression in the most currently studied tissues and provided a great deal of new information, mainly about the expression of mRNA of little-known CYP isoforms.
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.
The simple genotyping of 2 single-nucleotide polymorphisms (SNPs), VKORC1 -1639G>A or 1173C>T and the CYP2C9*3 polymorphisms, could predict a high risk of overdose before initiation of anticoagulation with acenocoumarol, and provide a safer and more individualized antICOagulant therapy.
Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1
Results provide strong evidence that P-450IIE1 is the primary catalyst of chlorzoxazone 6-hydroxylation in human liver and may have potential use as a noninvasive probe in estimating the in vivo expression of the protein.
Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy
It is suggested that in patients with SRL‐based therapy, genotyping of the CYP3As genes may help to optimize the SRL management in transplant recipients and that the variations in SRL requirements are secondary to both genetic and non‐genetic factors including pharmacokinetic interactions.
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Pharmacogenetic adaptation of the daily dose of tacrolimus is associated with improved achievement of the target C0, and whether this improvement will affect clinical outcomes requires further evaluation.
Human CYP2B6: expression, inducibility and catalytic activities.
Kinetic analysis showed that human CYP2B6 preferentially metabolized benzyloxyresorufin and pentoxyres orufin, although other CYPs also metabolized these substrates in human liver microsomes, and CYP1B6 manifested a strong 4-hydroxycyclophosphamide activity.
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
Genotype monitoring of the MDR1 gene reliably predicts the optimal dose of tacrolimus in renal transplant recipients and may predict the initial daily dose needed by individual patients to obtain adequate immunosuppression.
Human cytochromes P450